$DRMA News

Last published 1d ago

1d agoDRMADermata Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1d agoDRMADermata Therapeutics Provides Corporate Update and Reports Financial Results for the Third Quarter 2026ACCESS NewswireDermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions focused on the development and commercialization of consumer and professional skincare products, today highlighted recent corporate progress and reported financial results for the third quarter ended September 30, 2026. "The third quarter represents a transformational time for ...
6d agoDRMADermata Therapeutics Highlights Media Recognition of Tome Skincare Following Commercial LaunchACCESS Newswire- Tome Skincare featured in Cosmopolitan, Women's Wear Daily, AIR MAIL, and Thingtesting highlights Tome's growing recognition among leading beauty editors - SAN DIEGO, CA / ACCESS Newswire / November 5,
1w agoDRMADermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical TrialACCESS Newswire- Tome Clearing Treatment is Dermata's second once-weekly skincare product under its Tome brand -- Tome Clearing Treatment includes a salicylic acid wipe with Dermata's Bioneedle™ mask and is expected to launch
4w agoDRMADermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational TreatmentACCESS Newswire- Once-weekly Tome Foundational Treatment demonstrated improvements across key measures of skin appearance after four treatments -- Over 71% of study participants were graded as having overall improvements in their skin
2mo agoDRMADermata Therapeutics Announces Commercial Launch of Tome Foundational TreatmentACCESS Newswire- Tome Foundational Treatment, powered by Bioneedle™, is now available for purchase at www.tomeskincare.com -- Once-weekly Foundational Treatment is designed to renew the appearance of skin and improve tone and texture
2mo agoDRMADermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial LaunchACCESS Newswire- Preorders can be made by visiting www.tomeskincare.com -- Dermata is ready to begin shipping orders on the expected launch date of August 25, 2026 -- Tome Foundational Treatment is a once-weekly topical mask for skin
2mo agoDRMADermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq RulesACCESS Newswire$3.4 million upfront with up to approximately $6.7 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / August 17, 2026 / Dermata Therapeutics, Inc.
3mo agoDRMADermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026ACCESS Newswire- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 -- Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce
3mo agoDRMADermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational TreatmentACCESS Newswire- A new chapter in skincare has arrived -- This will be Dermata's first commercial product launch, planned for August 25, 2026 -- Join the waitlist at tomeskincare.com - SAN DIEGO, CA / ACCESS Newswire / August 5,
6mo agoDRMADermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026ACCESS Newswire- Dermata announced their Tome Skincare brand for direct-to-consumer skincare products -- Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to support skin
7mo agoDRMADermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery SystemACCESS Newswire- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System with dermal fillers -- The Company also has allowed and issued patents in the US, Australia, and Japan covering
7mo agoDRMADermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025ACCESS Newswire- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer skincare products under the brand name Tome -- Dermata plans to launch its first DTC product, our Foundational Treatment, a
8mo agoDRMADermata Announces Appointment of Kyra Peckaitis as Vice President, MarketingACCESS Newswire- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand -SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / Dermata Therapeutics, Inc.
8mo agoDRMADermata Opens a New Chapter with the Release of Tome SkincareACCESS Newswire-The oldest new thing in skincare -- Dermata expects to launch its first product in the middle of 2026 -SAN DIEGO, CA / ACCESS Newswire / March 5, 2026 / Dermata Therapeutics, Inc. ("Dermata"
9mo agoDRMADermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent OfficeACCESS NewswireThis patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat acneDermata expects to launch a new once-weekly, over-the-counter acne
10mo agoDRMADermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq RulesACCESS Newswire$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrantsSAN DIEGO, CA / ACCESS Newswire / December 29, 2025 / Dermata Therapeutics, Inc.
11mo agoDRMAA New Realm of Skincare is Coming: Dermata Teases New OTC Brand IdentityACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc. , a science-driven leader in dermatologic solutions, today
12mo agoDRMADermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial ResultsACCESS Newswire- Dermata announced a strategic pivot to develop and commercialize over-the-counter skin care treatments -- Dermata plans to launch its first OTC product, a once weekly acne kit with its Spongilla technology, in
1y agoDRMADermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent OfficeACCESS Newswire- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne -- Dermata expects to launch a new once-weekly, Over-the-Counter
1y agoACUT DRMA HMTXF INM+4Life Sciences Virtual Investor Forum: Presentations Now Available for Online ViewingGlobeNewswireNEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held
1y agoDRMADermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025ACCESS Newswire- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne - SAN DIEGO, CA / ACCESS Newswire / September 17, 2025 /
1y agoDRMADermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18thGlobeNewswireSAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th Dermata invites individual and institutional investors, as well as advisors and
1y agoDRMADermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care TreatmentsACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Dermata Therapeutics, Inc. , a science-driven leader in dermatologic solutions, today
1y agoDRMADermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsACCESS Newswire- Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research clinical trial-- Raised $8.8 million in gross proceeds from a private placement and warrant
1y agoDRMADermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsACCESS Newswire- Dermata announced positive topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research clinical trial, achieving all co-primary endpoints -- Dermata entered into a Clinical Trial
1y agoDRMADermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 WeeksACCESS Newswire- Dermata previously announced XYNGARI produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -- Additional data analysis revealed that XYNGARI separated from
1y agoDRMADermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq RulesACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. , a late-stage biotechnology company focused on the treatment of
1y agoDRMABREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary EndpointsPR NewswireDermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of...
1y agoDRMADermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial ResultsACCESS Newswire- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research clinical trial by end of March 2025 -- The Company recently entered into a Clinical Trial
1y agoDRMADermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for AcnePR NewswireDermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of...
1y agoDRMADermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for HyperhidrosisACCESS Newswire- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company recently entered into a Clinical Trial Collaboration
1y agoDRMADermata to Present on BioPub on January 31, 2025ACCESS Newswire- Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment community -SAN DIEGO, CA / ACCESS Newswire / January 29, 2025 /
1y agoDRMADermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne TreatmentACCESS Newswire- This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne -- Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ clinical
1y agoDRMADermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq RulesACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / January 23, 2025 / Dermata Therapeutics, Inc. , a late-stage biotechnology company focused on the treatment
1y agoDRMADermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq RulesACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Dermata Therapeutics, Inc. , a late-stage biotechnology company focused on the treatment
1y agoDRMA RVNCDermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)ACCESS NewswireThe Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari™ with Daxxify® to treat primary axillary hyperhidrosis -If successful, the Companies may explore clinical development in
1y agoDRMADermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)ACCESS Newswire- Xyngari is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 - SAN DIEGO, CA / ACCESSWIRE / December 16,
1y agoDRMADermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of AcneACCESS Newswire- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne -- Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 study for the treatment
1y agoDRMADermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneACCESS Newswire- STAR-1 topline results expected in March 2025 -- Over 30 million acne patients seek treatment in the U.S. each year -- Phase 2b for DMT310 achieved statistically significant results for all primary endpoints - SAN
1y agoDRMADermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsACCESS Newswire- Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research clinical trial -- Dermata continues discussions with potential botulinum toxin partners for DMT410 -- Raised
2y agoDRMADermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024GlobeNewswireSAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW)) ("Dermata" or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetics skin
2y agoDRMADermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024ACCESS NewswireSAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Dermata Therapeutics, Inc. , a late-stage biotechnology company focusing on the treatment of
2y agoDRMADermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq RulesACCESS NewswireDermata raises approximately $7.8 million in gross proceeds since May 2024 - expected to fund its operations into the second quarter of 2025SAN DIEGO, CA / ACCESSWIRE / September 17, 2024 / Dermata Therapeutics, Inc.
2y agoDRMADermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq RulesACCESS NewswireSAN DIEGO, CA / ACCESSWIRE / September 16, 2024 / Dermata Therapeutics, Inc. , a late-stage biotechnology company focused on the treatment of
2y agoDRMADermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024ACCESS NewswireSAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Dermata Therapeutics, Inc. ) , a late-stage biotechnology company focusing on the treatment of medical
2y agoDRMADermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsACCESS Newswire- DMT310 Phase 3 Spongilla Treatment of Acne Research clinical trial has enrolled over 50% of patients- Dermata continues discussions with potential botulinum toxin partners for DMT410- Raised $2.3 million in
2y agoDRMADermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneACCESS Newswire- STAR-1 topline results expected in first quarter of 2025 -- About 30 million acne patients seek treatment in the U.S. each year -- DMT310, if approved, could be the first once-weekly topical product for the treatment
2y agoDRMADermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq RulesACCESS NewswireSAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. , a late-stage biotechnology company focused on the treatment of medical
2y agoDRMADermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsACCESS Newswire- DMT310 Phase 3 Spongilla Treatment of Acne Research clinical trial enrollment remains on track -- Dermata continues discussions with potential botulinum toxin partners for DMT410 -- Received issuance of